



(51) International Patent Classification:

A61K 31/472 (2006.01) A61P 5/08 (2006.01)
A61K 9/14 (2006.01) A61K 9/48 (2006.01)
A61K 9/16 (2006.01) A61K 31/4709 (2006.01)
A61K 9/20 (2006.01)

(21) International Application Number:

PCT/US2021/049282

(22) International Filing Date:

07 September 2021 (07.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/076,024 09 September 2020 (09.09.2020) US

(71) Applicant: CRINETICS PHARMACEUTICALS, INC.

[US/US]; 10222 Barnes Canyon Road, Building #2, San
Diego, California 92121 (US).


(72) Inventors: **BURKE, Gerald**; 10222 Barnes Canyon Road,
Building #2, San Diego, California 92121 (US). **YATES,
Ian**; 1201 NW Wall Street, Suite 200, Bend, Oregon 97703
(US). **BULOVSKY, Hannah**; 1201 NW Wall Street, Suite
200, Bend, Oregon 97703 (US). **KYBURZ, Kyle**; 1201 NW
Wall Street, Suite 200, Bend, Oregon 97703 (US). **TYLER,
Clayton**; 1201 NW Wall Street, Suite 200, Bend, Oregon
97703 (US).

(74) Agent: **ZUNIC, Valentin B.**; WILSON SONSINI, 650
Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: FORMULATIONS OF A SOMATOSTATIN MODULATOR

Figure 1.



(57) Abstract: A spray-dried solid dispersion comprising: (a) 3 - [4 -(4 -amino -piperidin-1-yl)-3 -(3,5 -difluoro-phenyl)- quinolin-6 -yl] -2 -hydroxy-benzonitrile, or a pharmaceutically acceptable salt or solvate thereof; and (b) a pharmaceutically acceptable polymer; wherein said API is dispersed in a polymer matrix formed from the pharmaceutically acceptable polymer. A tablet comprising said the spray-dried solid dispersion and one or more pharmaceutical acceptable ingredients selected from the group consisting of one or more diluents, one or more disintegrants, one or more lubricants, one or more glidants. Said tablet for use in the treatment of acromegaly or neuroendocrine tumors, or both, in a human by oral administration.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*